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Abstract 1 
Linezolid is the first member of the oxazolidinones and is active against drug-resistant 2 
gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). 3 
Additionally, linezolid showed an immunomodulatory effect, such as an inhibition of the 4 
inflammatory cytokines production. In this study, we examined the effect of linezolid on 5 
MRSA-induced MUC5AC overexpression in airway epithelial cells. In this study, an MRSA 6 
supernatant was used to avoid the direct effect of linezolid on MRSA. MUC5AC protein 7 
production was significantly increased with a 40-fold dilution of MRSA supernatant. At the 8 
messenger RNA (mRNA) level, MUC5AC gene expression was significantly increased at 6 9 
and 9 hours after stimulation. In an inhibition study, linezolid significantly reduced 10 
MRSA-induced MUC5AC protein and mRNA overexpression at concentrations of 5 and 20 11 
µg/mL, which were same as the trough and peak concentrations in human epithelial lining 12 
fluid. In an analysis of cell signaling, among the mitogen-activated protein kinase inhibitors, 13 
only the extracellular signal–regulated protein kinase (ERK1/2) inhibitor reduced the 14 
MUC5AC protein production to the same level as that of the control; on Western blot 15 
analysis, only ERK1/2 was phosphorylated by the MRSA supernatant. In addition, the 16 
ERK1/2 phosphorylation was inhibited by linezolid. MUC5AC as well as MUC5B is the 17 
major barrier that traps inhaled microbial organisms, particulates, and foreign irritants. 18 
However, in patients with chronic respiratory diseases, pathogen-induced MUC5AC 19 
overexpression causes many problems, and control of the overexpression is important. Thus, 20 
this study revealed that linezolid showed the direct immunomodulatory effect in airway 21 
epithelial cells. 22 
 23 
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Introduction 1 
Linezolid is the first member of the oxazolidinones, a new class of antimicrobial 2 
agents. It acts by inhibiting the initiation of bacterial protein biosynthesis and is active against 3 
drug-resistant gram-positive pathogens such as methicillin-resistant Staphylococcus aureus 4 
(MRSA) and vancomycin-resistant enterococci, and it is one of the recommended antibiotics 5 
for patients with MRSA pneumonia in the guidelines for the management of 6 
hospital-acquired pneumonia (1) Linezolid also reduced a production of bacterial toxin (2-4). 7 
In addition, linezolid has been shown the direct immunomodulatory effects on inflammatory 8 
cells to inhibit the production of inflammatory cytokines such as interleukin (IL)-1 beta, IL-6, 9 
IL-8, and tumor necrosis factor alpha (5-7). The direct immunomodulatory effects of 10 
antimicrobial agents have been well elucidated with macrolides. Macrolides affect host cells 11 
by down-regulating inflammation, reducing production of reactive oxygen, inhibiting 12 
neutrophil activation and mobilization, accelerating neutrophil apoptosis, and blocking 13 
activation of nuclear transcription factors (8). Then, one of the immunomodulatory effects of 14 
the macrolides on human airway epithelial cells is the inhibition of pathogen-induced 15 
MUC5AC overexpression (9-14).  16 
MUC5AC and MUC5B are gel-forming mucins that are strongly expressed in the 17 
lung (15). The Mucin is the major barrier that traps inhaled microbial organisms, particulates, 18 
and foreign irritants in airway epithelium. In particular, MUC5B may play important roles in 19 
an airway defense, because loss of Muc5b gene reduced survival by causing bacterial 20 
infection in a murine model (16). In contrast,, MUC5AC overexpression was observed in 21 
patients with chronic respiratory diseases such as, diffuse panbronchiolitis and asthma (17), 22 
(18). The overexpression was also observed in patients with ventilator-associated pneumonia 23 
(VAP) (19). Since mucin overexpression causes airway obstruction, atelectasis, reduction of 24 
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oxygenation, and reduction of antibiotic permeability, inhibition of MUC5AC overexpression 1 
seemed to be useful. 2 
MUC5AC overexpression is induced by various pathogens, such as Pseudomonas 3 
aeruginosa, Escherichia coli, Haemophilus influenzae, Fusobacterium nucleatum, 4 
Chlamydophila pneumoniae, and Legionella pneumophila (9-14, 20, 21). MUC5AC 5 
overexpression also induced by peptidoglycan from S. aureus was reported (22). Although S. 6 
aureus, especially MRSA, is an important pathogen in patients with chronic respiratory 7 
diseases and VAP, there has been no study that has reported the effect of anti-MRSA 8 
antibiotics on MUC5AC overexpression. In addition, there was no report about direct 9 
immunomodulatory effect of linezolid on human airway epithelial cells. The purpose of this 10 
study was to reveal the direct immunomodulatory effect of linezolid by inhibition of 11 
MRSA-induced MUC5AC overexpression. 12 
13 
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Materials and Methods 1 
Materials 2 
Linezolid (Pfizer, Groton, CT, USA) was dissolved in distilled water. The mouse 3 
anti-MUC5AC monoclonal antibody (clone 45M1) was purchased from MONOSAN (Uden, 4 
the Netherlands). The goat anti-mouse horseradish peroxidase–conjugated secondary 5 
antibody was obtained from Bio-Rad (Hercules, CA, USA). The extracellular signal–6 
regulated protein kinase (ERK) inhibitor (U0126) was purchased from Promega (Madison, 7 
WI, USA). The p38 mitogen-activated protein kinase (MAPK) inhibitor (SB203580) and 8 
c-Jun N-terminal kinase (JNK) inhibitor II were purchased from Calbiochem (San Diego, CA, 9 
USA). The anti-ERK, anti–phospho-ERK1/2, anti-p38 MAPK, anti–phospho-p38 MAPK, 10 
anti-JNK, anti–phospho-JNK, anti-I-kappa B alpha (IkBa), and anti-phospho-IkBa antibodies 11 
were purchased from Cell Signaling Technology (Danvers, MA, USA). The ERK1/2 control 12 
cell extracts, p38 MAPK control cell extracts, JNK control cell extracts, and NF-kappa B 13 
(NF-kB) control cell extracts also purchased from Cell Signaling Technology (Danvers, MA, 14 
USA). 15 
 16 
Bacterial strain 17 
The MRSA strain used in this study was NUMR101, which was a clinical isolate 18 
obtained from the blood sample of a patient at the Nagasaki University Hospital (23). The 19 
bacteria were stored at −80ºC in a Microbank bead-based preservation system (Pro-Lab 20 
Diagnostics, Ontario, CA, USA) until use. The genetic characteristic of NUMR101 was 21 
identified by real-time polymerase chain reaction (PCR) using the same method as described 22 
in a previous report (24); the staphylococcal cassette chromosome mec (SCCmec) was type II, 23 
and the strain carried virulence genes such as sec and tsst but did not carry etb and pvl genes.  24 
 25 
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Preparation of MRSA supernatant 1 
To avoid the direct effect of linezolid on MRSA, we used an MRSA supernatant. The 2 
MRSA supernatant was prepared using a method modified described in our previous report 3 
(12). The NUMR101 strain was cultured on Mueller Hinton II agar (Becton, Dickinson and 4 
Company, Sparks, MD, USA) at 37ºC with 5% CO2 in fully humidified air. After overnight 5 
incubation, the NUMR101 strain was harvested and incubated in 10 mL of Luria-Bertani 6 
(LB) broth (MO BIO Laboratories, Carlsbad, CA, USA) at 37ºC with shaking at 250 rpm for 7 
72 hours. After incubation, the bacteria were centrifuged at 10,000g for 10 minutes at 4ºC, 8 
and the supernatant was filtered using a 0.22-µm Millex-GP filter (Millipore Corporation, 9 
Billerica, MA, USA). The MRSA supernatant was stored at −80ºC until use. 10 
 11 
Cell Culture 12 
The NCI-H292 (human airway epithelial) cell line was cultured in RPMI 1640 13 
medium supplemented with 10% fetal bovine serum (FBS). The cells were grown at 37ºC 14 
with 5% CO2 in fully humidified air. For the MUC5AC production studies, the cells were 15 
cultured in RPMI 1640 medium supplemented without FBS for 24 hours. After serum 16 
starvation, the cells were stimulated with the MRSA supernatant for enzyme-linked 17 
immunosorbent assay (ELISA) or reverse-transcription (RT)-PCR. The cells were treated 18 
with linezolid simultaneously with stimulation using the MRSA supernatant in the inhibition 19 
studies. In reference to the previous study, which reported the trough and peak concentrations 20 
of linezolid in the epithelial lining fluid (ELF) of patients with VAP (25), linezolid was used 21 
at 2 concentrations (5 and 20 µg/mL). Since there is possibility that LB broth induce 22 
MUC5AC overexpression, the controls were incubated with the same amount of LB broth as 23 
the MRSA supernatant. The cells were also pretreated with signal transduction inhibitors at 24 
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concentrations of 10 µM for 30 minutes before stimulation and the cells in the controls were 1 
incubated with only the medium and the same amount of dimethyl sulfoxide as the inhibitors. 2 
ELISA 3 
The MUC5AC protein level was measured using an enzyme-linked immunosorbent 4 
assay (ELISA) (10). The cells were cultured in 24-well plates, and after stimulation with the 5 
MRSA extracts for 24 hours, the culture medium was collected as the cell supernatant. The 6 
supernatant was then incubated at 40°C in a 96-well plate until dry. After incubation, the 7 
plates were blocked with 2% FBS for 1 hour at room temperature and then incubated with the 8 
anti-MUC5AC antibody diluted in phosphate-buffered saline containing 0.05% Tween 20 for 9 
1 hour. Horseradish peroxidase–conjugated anti-goat immunoglobulin G was then dispensed 10 
into each well. After 1 hour, the color developed using a 3,3′,5,5′-tetramethylbenzidine 11 
peroxidase solution, and the reaction was stopped by the addition of 1-N H2SO4. The 12 
absorbance was measured at 450 nm. 13 
 14 
RNA extraction and real-time quantitative RT-PCR 15 
Total RNA was extracted from the NCI-H292 cells cultured in 6-well plates using 16 
QuickGene Mini-80 and QuickGene RNA cultured cell kits (Kurabo Industries, Osaka, 17 
Japan) according to the manufacturer’s instructions. Total RNA (1 µg) was reverse 18 
transcribed into complementary DNA using oligo(dT) primers and SuperScript III reverse 19 
transcriptase (Invitrogen, Carlsbad, CA, USA) and then treated with RNase H. To quantify 20 
the expression of the MUC5AC gene, PCR primers and TaqMan probes were designed and 21 
used as reported previously (forward primer, 5′-CAGCCACGTCCCCTTCAATA-3′; reverse 22 
primer, 5′-ACCGCATTTGGGCATCC-3′; TaqMan probe, 23 
5′-6-FAM-CCACCTCCGAGCCCGTCACTGAG-TAMRA-3′) (11). The MUC5AC was 24 
amplified for 40 cycles (15 s at 95°C and 30 s at 60°C) using a LightCycler system (Rohce 25 
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Diagnostics, Basel, Switzerland). To normalize the MUC5AC expression, human 1 
porphobilinogen deaminase was also measured using specific PCR primers and TaqMan 2 
probes (forward primer, 5′-AACCAGCTCCCTGCGAAGA-3′; reverse primer, 3 
5′-CCAGGATGATGGCACTGAACT-3′; TaqMan probe, 4 
5′-FAM-ACTCCTGAACTCCAGATGCGGGAACT-TAMRA-3′) (26). 5 
 6 
Western blot analysis 7 
The cells were harvested at 0, 30, 60, and 90 min after MRSA stimulation and then 8 
washed and homogenized at 4ºC in lysis buffer (0.1% sodium dodecyl sulfate, 1% Igepal 9 
CA-630, and 0.5% sodium deoxycholate). The cell lysates (20–50 µg) were resolved by 10 
electrophoresis on a 12% polyacrylamide gel and transferred to a polyvinylidene difluoride 11 
membrane. After blocking the membrane using 10% FBS and 0.1% Tween 20 in 12 
Tris-buffered saline for 1 hour at room temperature, the blots were hybridized overnight at 13 
4ºC with primary antibodies. Hybridization with secondary antibodies was performed and the 14 
immunocomplexes were visualized using an ECL Western blotting detection reagent (GE 15 
Healthcare, Chalfont St. Giles, United Kingdom). 16 
 17 
Statistical analysis  18 
A statistical software package (StatMate IV for Windows; ATMS Co., Ltd., Tokyo, 19 
Japan) was used for all statistical comparisons. All data are expressed as mean and standard 20 
deviation (SD). One-way analysis of variance was used to determine the statistically 21 
significant differences between the groups. The Tukey test was used for pairwise comparison. 22 
All tests of significance were 2 tailed. The alpha level for denoting statistical significance 23 
was set at < 0.05.  24 
25 
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Results 1 
MRSA supernatant-induced MUC5AC protein production and gene overexpression 2 
Of the several concentrations of MRSA supernatant, only the 1/40-fold dilute solution 3 
of MRSA supernatant significantly increased the protein level of MUC5AC after 24 hours of 4 
stimulation (334.1 ± 150.3% greater than control, P < 0.05 vs. control) (Fig. 1A). To make 5 
sure that 72 hours incubation in the preparation of MURSA supernatant was most increased 6 
protein level of MUC5AC, 6 hours (mid-log phase) and 72 hours incubation were compared. 7 
The protein level of MUC5AC was 6.6 times higher in MRSA supernatant obtained from 72 8 
hours incubation than that from 6 hours incubation. Based on this result, the 1/40-fold dilute 9 
solution of MRSA supernatant obtained from 72 hours incubation was used for further 10 
studies. Subsequently, the influence of the MRSA supernatant on MUC5AC messenger RNA 11 
(mRNA) expression was evaluated. The cells were stimulated for 3, 6, and 9 hours, and the 12 
mRNA level of MUC5AC was assayed by RT-PCR. The MRSA supernatant significantly 13 
increased the mRNA level at 6 and 9 hours to approximately 4 times than that of the control 14 
(P < 0.01) (Fig. 1B).  15 
 16 
Linezolid inhibited MRSA supernatant-induced MUC5AC protein production and gene 17 
expression 18 
We then examined the effect of linezolid on MRSA supernatant-induced MUC5AC 19 
protein production and gene expression. Compared with the stimulation group, linezolid 20 
significantly reduced MRSA supernatant-induced MUC5AC protein production at 21 
concentrations of 5 and 20 µg/mL (373.6 ± 77.8% greater than control vs. 14.0 ± 68.8% 22 
greater than control [P < 0.001] and 373.6 ± 77.8% greater than control vs. 12.8 ± 13.8% 23 
greater than control [P < 0.001], respectively). However, this did not occur in a 24 
dose-dependent manner. At the mRNA level, linezolid significantly reduced MRSA 25 
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supernatant-induced MUC5AC mRNA expression at both concentrations compared with the 1 
stimulation group (16.1 ± 8.2 vs. 6.9 ± 1.8 [P < 0.001] and 16.1 ± 8.2 vs. 8.6 ± 3.2 [P < 2 
0.001], respectively) (Fig. 2B). 3 
  4 
Effect of MAPK inhibitors on MRSA supernatant-induced MUC5AC protein production 5 
 To reveal MRSA-induced activation of cell signaling, we examined the MAPK 6 
pathway that concerned MUC5AC protein production. The cells were treated with or without 7 
MAPK inhibitors (ERK inhibitor, p38 MAPK inhibitor, or JNK inhibitor), and the protein 8 
level of MUC5AC was evaluated by ELISA. Compared with the stimulation group, the ERK 9 
inhibitor significantly reduced MRSA-induced protein production to the same protein level as 10 
in the control at concentration of 10µM (88.7 ± 22.9% greater than control vs. 3.5 ± 37.1% 11 
greater than control, P < 0.01) (Fig. 3). The effect of ERK inhibitor was observed at 12 
concentration of 2 µM, but not at 0.4 µM (141.9 ± 11.2% greater than control [stimulation 13 
group] vs. -1.2 ± 5.3% greater than control [P < 0.01] and 159.3 ± 4.0% greater than control 14 
[not significant difference], respectively). In contrast, the p38 MAPK inhibitor and JNK 15 
inhibitor did not reduce protein production at concentration of 10µM (Fig. 3). 16 
 17 
Linezolid inhibited the phosphorylation of ERK in MRSA supernatant–activated 18 
NCI-H292 cells 19 
To demonstrate the effect of linezolid on the MAPK pathway, we examined the 20 
phosphorylation of MAPKs. As shown in Fig. 4A, the MRSA supernatant increased the 21 
phosphorylation of ERK1/2, which was inhibited by linezolid at a concentration of 5 µg/mL 22 
(Fig. 4A). In contrast, there was no significant change in the expression of p38 MAPK and 23 
JNK. The inhibitory effect of linezolid on the phosphorylation of ERK1/2 was also observed 24 
at a concentration of 20 µg/mL (Fig. 4B). Additionally, we also examined the activation of 25 
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MAPK pathway at 360 and 540 minutes in which MUC5AC mRNA overexpression was 1 
observed. At these times, only phosphorylation of ERK1/2 was observed (Fig. 5A). The anti–2 
phospho-p38 MAPK and anti–phospho-JNK antibodies worked with positive control cell 3 
extracts (Fig. 5B). Then, an influence of MRSA supernatant on NF-kB pathway was 4 
examined. As shown in Fig. 6, phosphorylation of IkBa was not observed in the western blot 5 
analysis. 6 
7 
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Discussion 1 
In this study, the MRSA-induced MUC5AC overexpression was inhibited by 2 
linezolid. The inhibitory effect on pathogen-induced MUC5AC overexpression has been 3 
reported as one of the immunomodulatory effects of macrolides (9-12, 14). MUC5AC as well 4 
as MUC5B is gel-forming mucin that is strongly expressed in the lung (15). They are the 5 
major barrier that traps inhaled microbial organisms, particulates, and foreign irritants in 6 
airway epithelium. In particular, MUC5B may play important roles in an airway defense, 7 
because a loss of Muc5b gene reduced survival by causing bacterial infection in a murine 8 
model (16). In contrast, the survival of mice was unaffected by a loss of Muc5ac gene. 9 
However, MUC5AC overexpression was observed in the Muc5b-/- mice, and it caused 10 
abnormal breathing and hypoxemia by impaired mucociliary clearance (16). In patients with 11 
chronic respiratory diseases such as, diffuse panbronchiolitis and asthma, MUC5AC 12 
overexpression was also observed (17, 18). In these diseases, mucin overexpression would 13 
cause airway obstruction, atelectasis, reduction of oxygenation, and reduction of antibiotic 14 
permeability. The overexpression is induced by various pathogens, such as Pseudomonas 15 
aeruginosa, Escherichia coli, Haemophilus influenzae, Fusobacterium nucleatum, 16 
Chlamydophila pneumoniae, and Legionella pneumophila (9-14, 20, 21). Thereby, it is very 17 
important to control pathogens-induced MUC5AC overexpression in patients with respiratory 18 
infectious diseases, and the inhibition of the overexpression was considered as the 19 
immunomodulatory effect of linezolid. 20 
The immunomodulatory effect of linezolid was reported in several studies. Some 21 
studies have shown that linezolid reduces the level of lipopolysaccharide-induced production 22 
of inflammatory cytokines in whole blood (5-7). Additionally, in the previous studies with 23 
methicillin-sensitive S. aureus and MRSA, linezolid has been shown to have an inhibitory 24 
effect on the pathogens-induced production of inflammatory cytokines (2-4). However, in 25 
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these studies, bacteria were co-cultured with linezolid, and linezolid also reduced the levels 1 
of toxin production (2-4). As a result, it was concluded that the inhibitory effect of linezolid 2 
on the production of cytokines is associated with a reduction in toxin production. In this study, 3 
we used a supernatant of MRSA culture without linezolid to avoid the direct effect of 4 
linezolid on MRSA, including the effect on toxin production. Accordingly, our results 5 
showed the direct immunomodulatory effect of linezolid on airway epithelial cells. 6 
Although S. aureus is one of the important pathogens causing respiratory tract 7 
infection or pneumonia, there have been few reports regarding the influence of S. aureus on 8 
MUC5AC production; one study used an S. aureus supernatant (20), and another used 9 
peptidoglycan from S. aureus (22). In this study, we revealed the mechanism of the 10 
overexpression. The mechanisms of MUC5AC overexpression in airway epithelial cell lines 11 
due to activation of MAPK pathway such as p38 MAPK and ERK1/2 has been reported at 12 
various stimulates (27), and the previous study using peptidoglycan from S. aureus reported 13 
that peptidoglycan-induced MUC5AC expression was activated the ERK1/2 pathway (22). 14 
This finding was similar to our results; in this study, only the ERK1/2 inhibitor reduced 15 
MUC5AC overexpression at the protein level. In western blot analysis, ERK1/2 was 16 
phosphorylated and p38 MAPK and JNK were not phosphorylated. Thus, activation of the 17 
ERK1/2 pathway seems to be specific to S. aureus-induced MUC5AC overexpression. 18 
Furthermore, we showed that the mechanism of the effect of linezolid: linezolid inhibited the 19 
phosphorylation of ERK1/2 in western blot analysis. The upper stream factors of ERK1/2, 20 
which was affected by MRSA and linezolid, was not investigated in this study, but the 21 
findings about the inhibitory effect of linezolid in MAPK pathway could suggest the direct 22 
effect of linezolid on airway epithelial cells. 23 
There are some limitations in this study. We used only 1 MRSA strain that is a 24 
clinical isolate obtained from our hospital, and there is some possibility that the MUC5AC 25 
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overexpression was strain specific. We did not compare the effect of linezolid with the other 1 
anti-MRSA agents, and it was not recognized whether the effect is a specific superior 2 
characteristics. However, we think that our results showed a possibility that the 3 
immunomodulatory effect of linezolid helps a treatment in the critically ill patients. In this 4 
study, linezolid showed the inhibition effect at a trough concentration in the ELF of patients 5 
with VAP (25). In patients with VAP, MRSA is the most common pathogen, and the 6 
mortality rate is as high as 32.2% (28). Additionally, mucin overexpression was also 7 
observed in the patients, and the overexpression contributes to impending mucociliary 8 
clearance and favor the colonization of Pseudomonas aeruginosa that is also the common 9 
pathogen in VAP (19). Consequently, the control of mucin overexpression seemed to be 10 
important in such patients, and linezolid might have a potential to inhibit the overexpression. 11 
In conclusion, our study showed that the MRSA supernatant-induced MUC5AC 12 
expression via activation of the ERK1/2 pathway and that linezolid inhibits MUC5AC 13 
overexpression. The inhibition effect was considered as a direct immunomodulatory effect on 14 
airway epithelial cells, and the effect has a possibility to help a treatment in patients with 15 
VAP caused by MRSA. 16 
17 
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Figure legends 1 
Fig. 1. Influence of the MRSA supernatant on MUC5AC protein production and gene 2 
expression. 3 
The NCI-H292 cells were stimulated with 1/80-, 1/40-, and 1/20-fold diluted 4 
solution of the MRSA supernatant. In the control, cells were stimulated with the same amount 5 
of LB broth as the supernatant. (A) After 24 hours of stimulation, the protein levels were 6 
measured by ELISA and provided in terms of percentage greater than control (n = 3). Of the 7 
3 concentrations, only the 1/40-fold dilute solution significantly increased the protein level of 8 
MUC5AC. (B) Cells were stimulated with the 1/40-fold dilute solution of the MRSA 9 
supernatant for 3, 6, and 9 hours. The mRNA level of MUC5AC was assayed by RT-PCR. 10 
The MRSA supernatant significantly increased MUC5AC mRNA expression at 6 and 9 hours. 11 
Results are expressed as the mean ± SD. *P < 0.05, **P < 0.01.  12 
ELISA, enzyme-linked immunosorbent assay; mRNA, messenger RNA; MRSA, 13 
methicillin-resistant Staphylococcus aureus; RT-PCR, reverse-transcription polymerase chain 14 
reaction  15 
 16 
Fig. 2. Effect of linezolid on MRSA supernatant-induced MUC5AC protein and gene 17 
overexpression.  18 
The NCI-H292 cells were treated with linezolid (5 µg/mL and 20 µg/mL). In the 19 
control, the cells were treated with culture medium only. (A) After 24 hours of treatment, the 20 
protein levels were measured by ELISA and provided in terms of percentage greater than 21 
control (n = 3). Linezolid significantly reduced the MRSA supernatant-induced protein 22 
production at both concentrations. (B) The cells were treated with linezolid for 6 hours, and 23 
the mRNA level of MUC5AC was assayed by RT-PCR. Linezolid inhibited MRSA 24 
supernatant-induced MUC5AC mRNA expression at both concentrations. Results are 25 
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expressed as the mean ± SD. *P < 0.001 compared with the stimulation group.  1 
ELISA, enzyme-linked immunosorbent assay; mRNA, messenger RNA; MRSA, 2 
methicillin-resistant Staphylococcus aureus; RT-PCR, reverse-transcription polymerase chain 3 
reaction 4 
 5 
Fig. 3. Effect of MAPK inhibitors on MUC5AC protein overexpression.  6 
The cells were treated with an ERK inhibitor, p38 MAPK inhibitor, or JNK 7 
inhibitor at concentration of 10µM. After 24 hours, the protein levels were evaluated by 8 
ELISA. Only the ERK inhibitor significantly reduced MRSA-induced MUC5AC protein 9 
production compared with the stimulation group. Results are expressed as the mean ± SD. *P 10 
< 0.01 compared with the stimulation group. 11 
ELISA, enzyme-linked immunosorbent assay; ERK, extracellular signal–regulated protein 12 
kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MRSA, 13 
methicillin-resistant Staphylococcus aureus. 14 
 15 
Fig. 4. Effect of linezolid on the MAPK pathway. 16 
     The NCI-H292 cells were treated with or without linezolid for 0, 30, 60, or 90 17 
minutes, and the cells were harvested after treatment and evaluated by western blotting. (A) 18 
The MRSA supernatant increased only phosphorylation of ERK1/2. The phosphorylation of 19 
ERK1/2 was inhibited by linezolid at a concentration of 5 µg/mL. There were no significant 20 
changes in other MAPKs, such as p38 MAPK and JNK. (B) The inhibitory effect of linezolid 21 
on the phosphorylation of ERK1/2 was observed at concentrations of 5 µg/mL and 20 µg/mL 22 
at 60 and 90 minutes. ERK, extracellular signal–regulated protein kinase; JNK, c-Jun 23 
N-terminal kinase; MAPK, mitogen-activated protein kinase; MRSA, methicillin-resistant 24 
Staphylococcus aureus. 25 
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 1 
Fig. 5. Influence of MRSA supernatant on the MAPK pathway. 2 
The NCI-H292 cells were stimulated with MRSA supernatant for 0, 180, 360, or 540 3 
minutes, and the cells were harvested after treatment and evaluated by western blotting. (A) 4 
The MRSA supernatant increased only phosphorylation of ERK1/2 at 180, 360, and 540 5 
minutes. In contrast, there were no significant changes in p38 MAPK and JNK. (B) The anti–6 
phospho-p38 MAPK and anti–phospho-JNK antibodies worked with positive control cell 7 
extracts. 8 
ERK, extracellular signal–regulated protein kinase; JNK, c-Jun N-terminal kinase; MAPK, 9 
mitogen-activated protein kinase; MRSA, methicillin-resistant Staphylococcus aureus. 10 
 11 
Fig. 6. Influence of MRSA supernatant on the NF-kB. 12 
The NCI-H292 cells were stimulated with MRSA supernatant, and the cells were 13 
harvested after treatment and evaluated by western blotting. (A) The MRSA supernatant did 14 
not activate the NF-kB pathway at 30, 60, and 90 minutes. (B) The MRSA supernatant did 15 
not activate the NF-kB pathway at 30, 60, and 90 minutes. (C) The anti–phospho-IkBa 16 
MAPK antibodiy worked with positive control cell extracts. 17 
NF-kB, NF-kappa-B; IkBa, I-kappa-B alpha; MRSA, methicillin-resistant Staphylococcus 18 
aureus. 19 
 20 






































 The NCI-H292 cells were stimulated with 1/80-, 1/40-, and 1/20-fold diluted solution of the MRSA supernatant. 
In the control, cells were stimulated with the same amount of LB broth as the supernatant. (A) After 24 hours 
of stimulation, the protein levels were measured by ELISA and provided in terms of percentage greater than 
control (n = 3). Of the 3 concentrations, only the 1/40-fold dilute solution significantly increased the protein level 
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Fig. 3. Effect of MAPK inhibitors on MUC5AC 
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Fig. 5. Influence of MRSA supernatant on the MAPK pathway.













The NCI-H292 cells were stimulated with MRSA supernatant for 0, 180, 360, or 540 minutes, and the cells were 
harvested after treatment and evaluated by western blotting. (A) The MRSA supernatant increased only 
phosphorylation of ERK1/2 at 180, 360, and 540 minutes. In contrast, there were no significant changes in p38 
MAPK and JNK. (B) The anti–phospho-p38 MAPK and anti–phospho-JNK antibodies worked with positive control 
cell extracts.
ERK, extracellular signal–regulated protein kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated 
protein kinase; MRSA, methicillin-resistant Staphylococcus aureus.














The NCI-H292 cells were stimulated with MRSA 
supernatant, and the cells were harvested after 





worked with positive control cell extracts.
1)N%1)NDSSD%,N%D,NDSSD%DOSKD056$
methicillin-resistant Staphylococcus aureus.
